Statin use and female reproductive organ cancer risk in a large population-based setting

被引:0
作者
Onchee Yu
Denise M. Boudreau
Diana S. M. Buist
Diana L. Miglioretti
机构
[1] Group Health Center for Health Studies,
[2] University of Washington,undefined
[3] Fred Hutchinson Cancer Research Center,undefined
来源
Cancer Causes & Control | 2009年 / 20卷
关键词
Statins; Endometrial cancer; Ovarian cancer; HMG-CoA reductase inhibitors;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:609 / 616
页数:7
相关论文
共 72 条
[1]  
Newman TB(1996)Carcinogenicity of lipid-lowering drugs JAMA 275 55-60
[2]  
Hulley SB(1996)The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators N Engl J Med 335 1001-1009
[3]  
Sacks FM(2002)Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 360 1623-1630
[4]  
Pfeffer MA(2002)HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis Leukemia 16 508-519
[5]  
Moye LA(2003)The statins as anticancer agents Clin Cancer Res 9 10-19
[6]  
Shepherd J(2000)3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case–control study Arch Intern Med 160 2363-2368
[7]  
Blauw GJ(2004)Statin use and cancer risk in the General Practice Research Database Br J Cancer 90 635-637
[8]  
Murphy MB(2007)Statin use and the risk of 10 cancers Epidemiology 18 213-219
[9]  
Wong WW(2005)Cancer risk among statin users: a population-based cohort study Int J Cancer 114 643-647
[10]  
Dimitroulakos J(2008)Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients Pharmacoepidemiol Drug Saf 17 27-36